Etanercept targets the BMPR2 pathway in part by inhibiting TNFα, a cytokine that is overexpressed in PAH patients and leads to the downregulation of BMPR2 mRNA in rat PAH models [160,211]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.